人凝血因子Ⅸ的线性B细胞表位预测及鉴定

为预测并鉴定人凝血因子IX(FIX)的线性B细胞表位.通过IEDB数据库及Discovery Studio软件预测FIX的B表位和白喉毒素T结构域(DTT)的B表位,用所预测的FIX的B表位替换某预测的DTT的B表位形成DTT-表位融合蛋白.通过基因工程技术制备各重组蛋白,并免疫小鼠,通过ELISA和Western-blot检测抗血清效价和特异性,通过等温量热滴定技术(ITC)测定抗体的亲和力.预测到4个FIX的B表位.用重组蛋白FIX-2-DTT免疫的小鼠产生了识别完整FIX的抗体,该抗体具有良好的特异性,其结合常数KD为106 M-1.表明FIX-2(306 NAAINKY312)是FIX的B表位,用重组蛋白FIX-2-DTT免疫小鼠能够产生特异性识别FIX且亲和力温和的抗体.     

小麦GLB1蛋白单克隆抗体的制备及鉴定

以小麦主要过敏原Glb-1蛋白为免疫原免疫BALB/c小鼠,取免疫小鼠脾细胞与小鼠骨髓瘤NS-1细胞融合。采用细胞融合和有限稀释法相结合的方法快速筛选获得稳定分泌的特异性杂交瘤细胞株,用杂交瘤细胞株诱生小鼠腹水并用蛋白A亲和层析法纯化抗体后检测。采用间接ELISA法鉴定该单克隆抗体的IgG亚型;通过间接ELISA鉴定该单克隆抗体的特性和交叉性。利用双单抗夹心ELISA法检测单抗的抗原表位特异性。结果表明:共获得4株可稳定分泌小鼠抗小麦主要过敏原Glb-1蛋白的单克隆抗体,分别命名为1C4、4H5、1A9、4F5,经检测其Ig亚型均为IgG1,且4株单抗效价均在10-9以上。ELISA结果分析表明该4株单抗均能特异性识别小麦主要过敏原Glb-1蛋白且和其他常见食物无交叉反应性。将4株单抗两两配对进行ELISA实验,结果发现1C4与4H5可能有不同的抗原表位,以此建立的双抗夹心ELISA系统可以检测小麦Glb1-G3蛋白。实验成功制备了鼠抗小麦主要过敏原Glb-1蛋白抗原的单克隆抗体,并且建立了双单抗夹心ELISA检测系统,为小麦主要过敏原蛋白的检测奠定了基础。     

人ZP3B-细胞表位嵌合肽DNA的设计和合成

目的：设计和合成适合在昆虫细胞中表达的一个人ＺＰ３ Ｂ细胞表位的ＤＮＡ序列。方法：根据国外的研究基础，设计由人ＺＰ３的Ｂ细胞表位肽段和外源Ｔｈ细胞表位肽段串联而成的４５肽嵌合肽序列，并根据昆虫细胞对密码子的偏爱性设计出该嵌合肽的ＤＮＡ序列。然后人工合成该嵌合肽的ＤＮＡ链，并克隆到ＰＵＣ１８载体上。结果：通过酶切分析和测序证明，合成的ＤＮＡ与所设计的嵌合肽ＤＮＡ序列一致。结论：按设计合成了人ＺＰ３的     

亲环素A抗原表位在三维结构中的初步定位

以抗人亲环素A单克隆抗体D4作捕获抗体，用噬菌体展示库鉴定出亲环素A模拟抗原表位的氨基酸序列为WSLQSFL，在亲环素A的一级结构中没有相同的序列，提示亲环素A抗原表位为构象型的，亲环素A的三维空间结构已测定，利用RasMol等蛋白质三维结构观察软件，可以初步确定亲环素A的抗原表位的时间位置，此抗原表位与环孢素的结合位点有重叠。     

Stepwise prediction and statistical screening: B-cell epitopes on neuraminidase of human avian H5N1 virus

The B-cell epitopes of virus are associated with the antiviral drug and the vaccine screening. As the nucleotide sequences of neuraminidase （NA） of stain GD-01-06 were sequenced, we predicted the a-helix and β-fold structure and the indexes of the flexible regions of secondary structure of NA with methods of the Hydrophilicity plot by Kyte-Doolittle, the Surface probability plot by Emini and the An- tigenic index by Jameson-Wolf, and then screened statistically the parameters to predict B-cell epi- topes by the Hierarchical cluster and the Bivariate correlation and the quartiles with SPSS 13.0. The impact of variation of amino acids in NA on its epitopes was analyzed. The predictive results were evaluated by Wu＇s Antigenic Index and SWISS-MODEL. We found that the most possible epitopes on NA were located within or nearby its N-terminal Nos. 120--137, 81--84, 408--415, 273--282, 429--432, 356--368, 46--55, 146--155, 341 --350 and 198--209, which were the dominant regions of NA epitopes. Peptide 120--137 including the glycoprotein domain （NGT126 128） was first chosen as the B-cell epitopes on NA. NA in H5N1 strain isolated after 2003 lacked in No. 53 amino acid （I）, resulting in an increase in the surface flexible region of NA in GD-01-06 and an enlargement to their epitope regions （VEP48-48→ VEPISNTNFL46-55）. Conclusively, prediction of the B-cell epitopes on the NA based on multiple pa- rameters is useful for researches on the molecular immunology and drug screening and immuno-prophylaxis. A deletion of No. 53 amino acid （I） in NA in strain GD-01-06 might increase its anti- genicity.     

含FMDV中和表位的重组病毒颗粒的构建及鉴定

针对FMDV的疫苗研究一直是防控口蹄疫的重点,而病毒样颗粒(VLPs)形式的疫苗因其安全性和近似传统灭活疫苗的良好免疫效果,近年来逐渐成为疫苗研究的一个新方向.本实验利用猪圆环病毒PCV2的衣壳蛋白(CAP)作为载体,分别插入FMDV MYA98毒株的抗原表位组合——VP1蛋白上B细胞表位141~160aa(B)与串联的B细胞和T细胞表位141~160aa-21~40aa-141~160aa(BTB),构建对应重组杆状病毒,分别命名为reBAC-CAP-B,reBAC-CAP-BTB.将上述病毒颗粒转入Sf9细胞表达,收获重组杆状病毒并再次感染Sf9细胞扩大病毒滴度,获得目的蛋白CAP-B,CAP-BTB,经过SDS-PAGE,Western blot鉴定正确,透射电镜观察到20~30nm大小的目的颗粒.     

HLA-A2限制性CTL表位肽定量构效关系研究

基于SCORE打分函数，运用定量构效关系的理论和方法研究了HLA—A2限制性CTL表位九肽结构与亲和性间的定量关系，并建立了SCORE得分与亲和性的定量关系模型，并用外部样本（5个HLA—A2限制性CTL表位九肽）作为预测集用于检验模型的预测能力．基于SCORE打分函数建立的定量模型具有较好的相关性（r=0，9165，RMS=0．38）和对外部样本的预测能力（rpred=0．9847，RMS=0．135）．基于SCORE打分函数，运用定量构效关系研究的理论和方法建立了HLA—A2限制性CTL表位亲和性的定量预测方法，为实验鉴定高亲和性HLA—A2限制性CTL表位提供了理论依据．     

Modeling the MHC class I pathway by combining predictions of proteasomal cleavage,TAP transport and MHC class I binding

Epitopes presented by major histocompatibility complex (MHC) class I molecules are selected by a multi-step process. Here we present the first computational prediction of this process based on in vitro experiments characterizing proteasomal cleavage, transport by the transporter associated with antigen processing (TAP) and MHC class I binding. Our novel prediction method for proteasomal cleavages outperforms existing methods when tested on in vitro cleavage data. The analysis of our predictions for a new dataset consisting of 390 endogenously processed MHC class I ligands from cells with known proteasome composition shows that the immunological advantage of switching from constitutive to immunoproteasomes is mainly to suppress the creation of peptides in the cytosol that TAP cannot transport. Furthermore, we show that proteasomes are unlikely to generate MHC class I ligands with a C-terminal lysine residue, suggesting processing of these ligands by a different protease that may be tripeptidyl-peptidase II (TPPII).Received 26 November 2004; received after revision 4 February 2005; accepted 4 March 2005S. Tenzer and B. Peters contributed equally to this work.     

Structural characteristics and biological functions of the HIV-1 gp120 V3 region

Recent studies demonstrate that the V3 loop of HIV-1 gp120 plays an important role in the attachment of HIV-1 to the target cells. Several amino acids in this domain are involved in the interaction of gp120 with the co-receptors. The V3 loop elicits one of the earliest antiviral antibody responses in HIV-1 infection and has been identified as the principal neutralizing determinant (PND). A subset of antibodies to V3 loop show a broad range of neutralizing activity. Unfortunately, this loop undergoes broad mutation and is one of the hypervariable regions. Mutations of some amino acids in this PND could affect syncytium formation, virus infectivity and neutralization. Knowing the structural characteristics and biological functions of the V3 region could help us to understand mechanism of HIV infection and to develop new strategy against HIV-1. In this review, the structural characteristics, variation and biological functions of the V3 loop as well as immunological responses to the V3 loop are discussed.